Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation.

Lung cancer (Amsterdam, Netherlands) - 1 Aug 2020

Yang Yu-Mi, Jang Yoon, Lee Sang Hyuk, Kang Beodeul, Lim Sun Min

Abstract excerpt

OBJECTIVES: In non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, acquired resistance to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) may occur via bypass signals such as AXL or MET activation. We investigated the antitumor activity of CB469, a newly developed drug that targets both AXL and MET, in EGFR TKI-resistant NSCLC cells. MATERIALS AND METHODS: We generated EGFR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Proliferation

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 32521387
DOI: 10.1016/j.lungcan.2020.05.031

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation.PMID 32521387Read ↗

244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.Semantic proximity Read ↗

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model.Semantic proximity Read ↗

Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapySemantic proximity Read ↗

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.Semantic proximity Read ↗

S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.Semantic proximity Read ↗

Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).Semantic proximity Read ↗

Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation.Semantic proximity Read ↗

Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC.Semantic proximity Read ↗

A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC.Semantic proximity Read ↗

Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds.Semantic proximity Read ↗

Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer.Semantic proximity Read ↗

A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.